M&A Deal Summary

Kite Pharma Acquires T-Cell Factory B.V.

On March 17, 2015, Kite Pharma acquired life science company T-Cell Factory B.V. for 20M EUR

Acquisition Highlights
  • This is Kite Pharma’s 1st transaction in the Life Science sector.
  • This is Kite Pharma’s 2nd largest (disclosed) transaction.
  • This is Kite Pharma’s 1st transaction in the Netherlands.

M&A Deal Summary

Date 2015-03-17
Target T-Cell Factory B.V.
Sector Life Science
Buyer(s) Kite Pharma
Deal Type Add-on Acquisition
Deal Value 20M EUR

Target

T-Cell Factory B.V.

Netherlands
T-Cell Factory B.V. develops tumor-specific TCRs for broad application in cancer treatment based on its proprietary TCR-GENErator™ platform.

Search 214,107 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Kite Pharma

Santa Monica, California, United States

Category Company
Founded 2009
Sector Life Science
Employees184
Revenue 22M USD (2016)
DESCRIPTION
Kite Pharma's corporate headquarters in Santa Monica, California.
Kite Pharma's corporate headquarters in Santa Monica, California.

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT designed to restore the immune system's ability to recognize and eradicate tumors. Kite Pharma was formed in 2009 and is based in Santa Monica, California.


DEAL STATS #
Overall 1 of 4
Sector: Life Science M&A 1 of 4
Type: Add-on Acquisition M&A Deals 1 of 3
Country: Netherlands M&A 1 of 1
Year: 2015 M&A 1 of 1
Size (of disclosed) 2 of 3
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-07 Cell Design Labs

Emeryville, California, United States

Cell Design Labs, Inc. is a biotherapeutics company pioneering breakthrough science to develop disruptive therapies for cancer and other devastating diseases. Cell Design Labs, Inc. was founded in 2015 and is based in San Emeryville, California.

Buy $567M